August 20, 2020
Article
Intravenous (IV) fosfomycin offers a novel therapeutic option in the treatment of systemic multi-drug resistant (MDR) infections. Unanswered questions remain regarding its efficacy and specific role in our therapeutic arsenal.
Oral Sabizabulin Reduces COVID-19 Deaths in High-Risk Adults
Pneumonic Plague in an Era of COVID-19
FDA: Pharmacists Can Prescribe Paxlovid to Eligible Patients
Utilizing Global Surveillance to Develop a Syphilis Vaccine